Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

KNSA

Kiniksa Pharmaceuticals International, plc

Pharmaceutical Preparations · SIC 2834CIK 1730430Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$678.0M
Net Income FY2025
$59.0M
EPS (Basic, as reported)
$0.80
Net Margin FY2025
8.7%
ROE FY2025
10.4%
Total Equity
$568.0M
Shares Out
—
Business description

Kiniksa Pharmaceuticals International, plc — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 39 → 678 +104.2% CAGR
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue————39220270423678
Cost of revenue————(9)(23)(33)(61)(78)
Research & development(56)(87)(135)(112)(99)(65)(76)(112)(97)
Selling, general & administrative——(35)(45)(86)(98)(129)(168)(196)
General & administrative(9)(22)(35)(45)—————
Total operating expenses(65)(108)(170)(157)—————
Operating income(65)(108)(170)(157)(157)10(25)(46)77
Interest & investment income1561018912
Pre-tax income(65)(103)(164)(156)(157)11(17)(36)89
Income tax expense00(2)(5)(1)(172)(31)(7)(30)
Net income(65)(103)(162)(161)(158)18314(43)59
EPS — basic——($2.99)($2.61)($2.30)$2.64$0.20($0.60)$0.80
EPS — diluted——($2.99)($2.61)($2.30)$2.60$0.20($0.60)$0.75
Shares outstanding — basic (M)——54626969707174
Shares outstanding — diluted (M)——54626970727179

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.